MRP as a new predictive marker of tamoxifen efficiency in treatment of estrogen receptor-positive breast cancer

Dokl Biochem Biophys. 2010 Jan-Feb:430:36-40. doi: 10.1134/s1607672910010114.

Authors

T A Bogush¹, E A Dudko, E A Bogush, M V Tikhomirov, V Yu Kirsanov, M I Davydov

Affiliation

¹ N.N. Blokhin Russian Cancer Research Center of the Russian Academy of Medical Sciences, Kashirskoe sh. 24, Moscow, 115478 Russia.

PMID: 20380160
DOI: 10.1134/s1607672910010114

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

ATP Binding Cassette Transporter, Subfamily B, Member 1 / immunology
ATP Binding Cassette Transporter, Subfamily B, Member 1 / metabolism*
Animals
Antibodies / immunology
Antibody Specificity
Antineoplastic Agents, Hormonal / pharmacology
Antineoplastic Agents, Hormonal / therapeutic use
Biomarkers, Tumor / immunology
Biomarkers, Tumor / metabolism*
Breast Neoplasms / drug therapy*
Breast Neoplasms / metabolism*
Female
HeLa Cells
Humans
Receptors, Estrogen / metabolism*
Staining and Labeling
Tamoxifen / pharmacology*
Tamoxifen / therapeutic use*

Substances

ATP Binding Cassette Transporter, Subfamily B, Member 1
Antibodies
Antineoplastic Agents, Hormonal
Biomarkers, Tumor
Receptors, Estrogen
Tamoxifen